BR112019018088A2 - Composições propositadamente selecionadas que compreendem canabinoides purificados e/ou terpenos purificados - Google Patents

Composições propositadamente selecionadas que compreendem canabinoides purificados e/ou terpenos purificados Download PDF

Info

Publication number
BR112019018088A2
BR112019018088A2 BR112019018088-5A BR112019018088A BR112019018088A2 BR 112019018088 A2 BR112019018088 A2 BR 112019018088A2 BR 112019018088 A BR112019018088 A BR 112019018088A BR 112019018088 A2 BR112019018088 A2 BR 112019018088A2
Authority
BR
Brazil
Prior art keywords
purified
propositally
canabinoids
terpens
understand
Prior art date
Application number
BR112019018088-5A
Other languages
English (en)
Inventor
Levy Kurt
Michael Cooper Jonathan
Reed Martin Jonathan
Geoffrey Reid Brian
Original Assignee
Canopy Growth Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/616,874 external-priority patent/US20170266153A1/en
Application filed by Canopy Growth Corporation filed Critical Canopy Growth Corporation
Publication of BR112019018088A2 publication Critical patent/BR112019018088A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyrane Compounds (AREA)

Abstract

são aqui reveladas novas composições que compreendem um canabinoide purificado e um terpeno purificado. em uma modalidade, as composições compreendem um ou mais canabinoides purificados. em uma modalidade, as composições compreendem um ou mais canabinoides purificados em combinação com um ou mais terpenos purificados. em uma modalidade, as composições compreendem razões de ocorrência não natural. em uma modalidade, as composições compreendem concentrações de ocorrência não natural. em uma modalidade, as composições compreendem efeitos inesperados e/ou sinérgicos.
BR112019018088-5A 2017-03-01 2018-03-01 Composições propositadamente selecionadas que compreendem canabinoides purificados e/ou terpenos purificados BR112019018088A2 (pt)

Applications Claiming Priority (35)

Application Number Priority Date Filing Date Title
US201762465688P 2017-03-01 2017-03-01
US62/465.688 2017-03-01
US201762469415P 2017-03-09 2017-03-09
US62/469.415 2017-03-09
US201762475153P 2017-03-22 2017-03-22
US62/475.153 2017-03-22
US201762477990P 2017-03-28 2017-03-28
US62/477.990 2017-03-28
US201762489360P 2017-04-24 2017-04-24
US62/489.360 2017-04-24
US201762490465P 2017-04-26 2017-04-26
US201762490567P 2017-04-26 2017-04-26
US62/490.567 2017-04-26
US62/490.465 2017-04-26
US201762491160P 2017-04-27 2017-04-27
US201762491175P 2017-04-27 2017-04-27
US62/491.175 2017-04-27
US62/491.160 2017-04-27
US201762491980P 2017-04-28 2017-04-28
US201762491899P 2017-04-28 2017-04-28
US62/491.899 2017-04-28
US62/491.980 2017-04-28
US201762509651P 2017-05-22 2017-05-22
US62/509.651 2017-05-22
US201762510229P 2017-05-23 2017-05-23
US62/510.229 2017-05-23
US201762510660P 2017-05-24 2017-05-24
US201762510672P 2017-05-24 2017-05-24
US62/510.672 2017-05-24
US62/510.660 2017-05-24
US201762511218P 2017-05-25 2017-05-25
US62/511.218 2017-05-25
US15/616.874 2017-06-07
US15/616,874 US20170266153A1 (en) 2015-02-27 2017-06-07 Compositions purposefully selected comprising purified cannabinoids and/or purified terpenes
PCT/US2018/020440 WO2018160827A1 (en) 2017-03-01 2018-03-01 Compositions purposefully selected comprising purified cannabinoids and/or purified terpenes

Publications (1)

Publication Number Publication Date
BR112019018088A2 true BR112019018088A2 (pt) 2020-03-24

Family

ID=63370542

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019018088-5A BR112019018088A2 (pt) 2017-03-01 2018-03-01 Composições propositadamente selecionadas que compreendem canabinoides purificados e/ou terpenos purificados

Country Status (10)

Country Link
EP (1) EP3589129A4 (pt)
CN (1) CN110582206A (pt)
AU (1) AU2018227544A1 (pt)
BR (1) BR112019018088A2 (pt)
CA (1) CA3054690A1 (pt)
CO (1) CO2019009413A2 (pt)
IL (1) IL268929A (pt)
MX (1) MX2019010370A (pt)
PE (1) PE20200383A1 (pt)
WO (1) WO2018160827A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3743055B1 (en) 2018-01-23 2024-03-06 High Sierra Technologies, Inc. Cannabis products modified by removing volatile organic compounds
IL266151A (en) * 2019-04-18 2019-07-31 Kanabo Res Ltd Dilute for the cannabinoid preparations
CA3148236A1 (en) 2019-07-22 2021-01-28 Canopy Growth Corporation Continuous crystallization of cannabinoids in a stirred-tank reactor
CN114980882A (zh) * 2019-11-26 2022-08-30 乐康瑞德有限公司 大麻素和番茄红素抗炎协同组合
WO2021220208A1 (en) * 2020-04-29 2021-11-04 Ligar Limited Partnership Imprinted polymers and methods for their use
EP4188915A1 (en) * 2020-07-27 2023-06-07 Canopy Growth Corporation Methods of synthesizing cannabielsoin and analogs thereof
US20240342197A1 (en) * 2021-01-29 2024-10-17 The Johns Hopkins University Limonene effects on tetrahydrocannabinol (thc)-induced anxiety
CN113368086B (zh) * 2021-08-11 2021-12-03 龙麻(上海)医药研发有限责任公司 一种大麻素组合物及其在制备治疗帕金森、阿尔茨海默等神经退行性疾病的药物中的应用
WO2023245185A1 (en) * 2022-06-17 2023-12-21 New Growth Brands, Inc. Compositions comprising cannabinoids and methods of preparation and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009019322A1 (de) * 2009-04-30 2010-11-11 The Health Concept Gmbh Verfahren zur Herstellung von Synthetischen Cannabinoiden
GB2478595B (en) * 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
TWI583374B (zh) * 2010-03-30 2017-05-21 Gw伐瑪有限公司 使用植物大麻素次大麻二酚(cbdv)來治療癲癇之用途
EP3071193B1 (en) * 2013-11-20 2020-01-08 Panag Pharma Inc. Compositions and methods for treatment of ocular inflammation and pain
CA2977802A1 (en) * 2015-02-27 2016-09-01 Ebbu, LLC Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral

Also Published As

Publication number Publication date
IL268929A (en) 2019-10-31
EP3589129A1 (en) 2020-01-08
EP3589129A4 (en) 2020-11-25
CN110582206A (zh) 2019-12-17
CO2019009413A2 (es) 2019-09-09
MX2019010370A (es) 2019-10-22
WO2018160827A1 (en) 2018-09-07
AU2018227544A1 (en) 2019-08-29
CA3054690A1 (en) 2018-09-07
PE20200383A1 (es) 2020-02-24

Similar Documents

Publication Publication Date Title
BR112019018088A2 (pt) Composições propositadamente selecionadas que compreendem canabinoides purificados e/ou terpenos purificados
BR112017018316A2 (pt) composições compreendendo combinações de canabinoides purificados, com pelo menos um flavonoide, terpeno ou mineral
BR112017017217A2 (pt) ?composição que compreende ramnolipídeo e siloxano?
MX2019000427A (es) Formas de dosificacion oral de cannabinoide de alta concentracion.
CL2017002335A1 (es) Composiciones de cosmetica topica para combatir radicales libres
BR112017018276A2 (pt) ?composição que compreende peptidase e biotensoativo e seu uso?
CL2020000632A1 (es) Composición y método para el tratamiento del autismo.
BR112017004826A2 (pt) terapias de combinação de inibidores de alk
PH12019501323A1 (en) Compositions comprising sulfated polysaccharides
PE20200338A1 (es) Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil
AR100562A1 (es) Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
BR112018070060A2 (pt) composições para tratamento bucal com uma exibição de sabor eficiente
MX2016014509A (es) Formulacion de vitamina soluble en grasa.
BR112015029987A8 (pt) Beta-caseína a2 e a prevenção de inflamação do intestino
BR112017006180A2 (pt) composições de redução de mau odor
BR112018003780A2 (pt) composições que compreendem um composto de urolitina
BR112017019352A2 (pt) composições tópicas comprimidas a corticosteróide aplicações relacionadas
BR112017008962A2 (pt) proteínas de fusão inibidoras de c1 esterase e usos das mesmas
BR112021019262A2 (pt) Uso de ciclo-his-pro (chp) para prevenir, atenuar ou tratar fibrose
UY38284A (es) Composiciones y métodos para agonizar el receptor cb2
BR112018068817A2 (pt) beta-caseínas e função cognitiva
CL2019000174A1 (es) Composición vaginal que comprende una combinación de estrógeno y vitamina d.
BR112017018618A2 (pt) odorizante de osmanthus
CO2020003134A2 (es) Moduladores de la expresión de enac
BR112018013558A2 (pt) método de tratamento de uma doença hepática em um indivíduo, método de uso de um inibidor de caspase, método para diminuir ou sustentar uma classificação meld ou seus componentes, método para tratar, diminuir ou sustentar uma classificação meld ou seus componentes, método para tratar, diminuir ou sustentar uma classificação de child-pugh ou seus componentes, composição farmacêutica que compreende um inibidor de caspase, kit, método de tratamento, método de tratamento de cirrose hepática e prevenção de uma classificação meld elevada, método de tratamento de cirrose hepática e prevenção de uma classificação de child-pugh elevada

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]